CN110467667A - 一种抗肿瘤活性肽及其应用 - Google Patents
一种抗肿瘤活性肽及其应用 Download PDFInfo
- Publication number
- CN110467667A CN110467667A CN201910825743.5A CN201910825743A CN110467667A CN 110467667 A CN110467667 A CN 110467667A CN 201910825743 A CN201910825743 A CN 201910825743A CN 110467667 A CN110467667 A CN 110467667A
- Authority
- CN
- China
- Prior art keywords
- active peptide
- peptide
- artificial sequence
- present
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 55
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 description 12
- 239000012071 phase Substances 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000010828 elution Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229910021642 ultra pure water Inorganic materials 0.000 description 8
- 239000012498 ultrapure water Substances 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000001641 gel filtration chromatography Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 2
- CAVKXZMMDNOZJU-UHFFFAOYSA-N Gly-Pro-Ala-Gly-Pro Natural products C1CCC(C(O)=O)N1C(=O)CNC(=O)C(C)NC(=O)C1CCCN1C(=O)CN CAVKXZMMDNOZJU-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- -1 elixir Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 1
- HPNDBHLITCHRSO-WHFBIAKZSA-N Asp-Ala-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(O)=O HPNDBHLITCHRSO-WHFBIAKZSA-N 0.000 description 1
- AXXCUABIFZPKPM-BQBZGAKWSA-N Asp-Arg-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O AXXCUABIFZPKPM-BQBZGAKWSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 1
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 1
- MHHUEAIBJZWDBH-YUMQZZPRSA-N Gly-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN MHHUEAIBJZWDBH-YUMQZZPRSA-N 0.000 description 1
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 1
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 1
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 1
- OEROYDLRVAYIMQ-YUMQZZPRSA-N His-Gly-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O OEROYDLRVAYIMQ-YUMQZZPRSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004833 fish glue Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开一种抗肿瘤活性肽及其应用。本发明所述活性肽的氨基酸序列如SEQ ID NO:1‑SEQ ID NO:5所示。本发明提供的活性肽具有较好的抗肿瘤活性，尤其可以显著抑制卵巢癌细胞的增殖，可用于抗肿瘤药物和保健品的开发。
Description
技术领域
本发明涉及活性肽技术领域。更具体地，涉及一种抗肿瘤活性肽及其应用。
背景技术
胶原蛋白属于结构蛋白，广泛存在于真皮、骨、鳞、鳔、肌肉、软骨等结缔组织中。同时也是哺乳动物体内含量最多，分布最广的功能性蛋白。胶原蛋白种类繁多，以Ⅰ型、Ⅱ型、Ⅲ型、Ⅳ型、Ⅺ型较为常见。胶原蛋白具有良好的生物相容性，可生物降解性，并具有多种生物活性，比如抗癌、抗氧化、增强免疫、调节骨代谢等，因此广泛应用于食品、医药、组织工程等领域。
生物活性肽是指对生物机体的生命活动有益或具有生理作用的肽类化合物。活性肽的结构可以从较小的二肽到较大分子的多肽。而且生物活性肽来源非常广泛，包括动物、植物、微生物等。生物活性肽制备方法包括酸法、碱法和酶法，其中以酶法制备生物活性肽较为普遍，目前，市面上很多骨胶原蛋白来源的活性肽多为骨胶原蛋白的酶解产物，而没有单一纯化后的活性肽产品，产品成分不明确，在后期药物和保健品开发过程会遇到各种问题。
发明内容
本发明的第一个目的在于提供牛骨胶原蛋白来源的活性肽。
本发明的第二个目的在于提供上述活性肽在抗肿瘤方面的应用。
为达到上述目的，本发明采用下述技术方案：
根据本发明的第一个目的，本发明提供一种活性肽，所述活性肽的氨基酸序列包括如下序列中的一种或多种：
DAGPVG，如SEQ ID NO:1所示；
ERGEEGPAG，如SEQ ID NO:2所示；
HGDRGELGPAG，如SEQ ID NO:3所示；
ADGDRGEAGPAGPAGPAGPR，如SEQ ID NO:4所示；
GPAGPEGPRGDKGETGEEGDR，如SEQ ID NO:5所示。
可选的，所述活性肽还可以是与上述任一活性肽的氨基酸序列具有80％及以上同源性的活性肽，该活性肽和上述活性肽的功能相同或相似。例如，所述活性肽的氨基酸序列可以是与上述任一活性肽的氨基酸序列具有85％，90％，95％或97％同源性的序列。
本发明还提供了编码上述活性肽的多核苷酸。
在已知活性肽的氨基酸序列的情况下，本领域技术人员可以根据对于活性肽表达的需要，基于密码子的简并性原则和不同物种对于密码子的使用偏好性，设计具有不同核苷酸序列的活性肽的编码基因。
在本发明中，示例性的，上述活性肽的核苷酸序列如序列表SEQ ID NO:6-SEQ IDNO:10所示。
本发明的活性肽可以从牛骨胶原蛋白酶解产物中经过分离纯化获得，也可以通过本领域已知的其他方法制备得到，例如固相合成的方法、生物工程的方法等等。
根据本发明的第二个目的，本发明提供所述活性肽在制备抗肿瘤药物或保健品中的应用。优选的，用于抗女性卵巢癌。从而本发明进一步涉及一种药物或一种保健品，其中含有本发明的活性肽，例如DAGPVG，ERGEEGPAG，HGDRGELGPAG，ADGDRGEAGPAGPAGPAGPR，和GPAGPEGPRGDKGETGEEGDR中的一种或多种。
本发明的药物和保健品可以制成本领域常见的各种形式，包括但不限于，适于口服的散剂、片剂(包括各种包衣片剂、缓释或控释片剂)、锭剂、胶囊剂(包括软胶囊和硬胶囊)、颗粒剂、丸剂、可分散粉末、水性或油性混悬剂、水性或油性溶液剂、乳剂、酏剂、糖浆剂等等，适于局部使用的霜剂、软膏剂、凝胶、水性或油性溶液剂、水性或油性混悬剂等等；适于吸入使用的粉末或液体气雾剂；适于经胃肠外给药的静脉内、皮下或肌内注射用无菌水性或油性的注射剂或冻干粉针剂、栓剂等等。
本发明的药物和保健品中可以进一步含有常规的各种辅料和/或其他活性成分。合适的辅料包括但不限于赋形剂、润滑剂、粘合剂、崩解剂、水溶性聚合物、无机盐、溶剂、溶解助剂、悬浮剂、等渗剂、缓冲液、防腐剂、抗氧剂、着色剂、甜味剂、酸味剂、起泡剂和调味剂等等。
本发明的有益效果如下：
本发明以MTT细胞毒活性为追踪指标，将牛骨胶原蛋白酶解产物依次进行反相硅胶柱层析、凝胶柱层析以及高效液相色谱，并对活性最强的组分进行LC-MS-MS分析，最终鉴定到5种具有较强抗肿瘤细胞活性的活性肽，尤其可以显著抑制卵巢癌细胞的增殖。
附图说明
下面结合附图对本发明的具体实施方式作进一步详细的说明。
图1示出超滤组分CP1的快速反相硅胶柱层析色谱图。
图2示出超滤组分CP1经过快速反相硅胶柱层析得到的6个组分的MTT细胞毒活性测试结果。
图3示出快速反相硅胶柱层析组分CP1-1凝胶色谱图。
图4示出快速反相硅胶柱层析组分CP1-1经过凝胶柱层析得到的3个组分的MTT细胞毒活性测试结果。
图5示出凝胶柱层析组分CP1-1-1反相高效液相色谱图。
图6示出凝胶柱层析组分CP1-1-1经过反相高效液相色谱纯化得到的3个组分的MTT细胞毒活性测试结果。
图7示出采用MTT法验证本发明5种活性肽的细胞毒活性测试结果。
具体实施方式
为了更清楚地说明本发明，下面结合优选实施例和附图对本发明做进一步的说明。本领域技术人员应当理解，下面所具体描述的内容是说明性的而非限制性的，不应以此限制本发明的保护范围。
实施例1活性肽制备
依据中国专利申请CN 105586379 A“一种具有抑制癌细胞增殖作用的胶原蛋白活性肽的制备方法”公开的内容，获得超滤组分CP1，即完成该专利申请中所公开的制备方法的步骤(1)-(8)。
反相硅胶柱层析：使用ODS-AQ反相硅胶柱(50μm,mm×100mm)对生物活性肽进行分离纯化。采用无水乙醇-超纯水为流动相以流速5mL/min对超滤截留的CP1进行梯度洗脱。洗脱条件为：100％的超纯水洗脱10min；96％的超纯水洗脱20min；90％的超纯水洗脱20min；87％的超纯水冲洗20min；83％的超纯水洗脱5min；78％的超纯水洗脱10min；100％的无水乙醇洗脱12min。220nm为检测波长，分别收集到6个洗脱峰并冷冻干燥放-80℃低温冰箱保存待用，结果见图1。对6个组分进行MTT细胞毒活性测试，结果如图2所示。CP1-1具有最强的细胞毒活性，遂对此组分进行进一步分离。
凝胶柱层析：对反相硅胶柱层析分离得到的最强活性的组分CP1-1采用Superdex75 10/300GL凝胶柱层析进行进一步纯化。凝胶柱首先用约50mL 20mM磷酸缓冲液(PH＝4.2)进行平衡,之后上样，以0.3mL/min的流速，对样品进行洗脱，所用的流动相为20mM磷酸缓冲液(PH＝4.2)。220nm为检测波长，收集到3个洗脱峰并冷冻干燥放-80℃低温冰箱备用，结果见图3。对3个组分进行MTT细胞毒活性测试，结果如图4所示。CP1-1-1具有最强的细胞毒活性，遂对此组分进行下一步分离。
高效液相色谱：对凝胶柱分离得到的活性最强的组分CP1-1-1采用高效液相色谱进行进一步纯化。ODS-AQ反相柱(20μm,2.5mm×150mm)首先用100％的超纯水平衡至基线呈一条直线，之后上样，以流速1mL/min对样品进行梯度洗脱。色谱条件为：100％的超纯水洗脱3min；100％的色谱乙腈洗脱12min。收集3个主要色谱峰并冷冻干燥放-80℃备用，结果见图5。对3个组分进行MTT细胞毒活性测试，结果如图6所示。CP1-1-1-2具有最强的细胞毒活性，遂对此组分进行LC-MS-MS分析。
利用液相色谱质谱联用仪对活性最强的组分CP1-1-1-2进行氨基酸序列分析，共鉴定到5条活性肽。结果见表1。
表1 从牛骨胶原蛋白酶解液中鉴定到的活性肽序列
实施例2
基于实施例1鉴定得到的5种活性肽的氨基酸序列，通过固相合成方法获得实验样品，进行抗肿瘤活性验证。结果表明活性肽具有较强的细胞毒活性，结果如图7所示。
固相合成肽公司：吉尔生化(上海)有限公司。
细胞毒活性的检测：
首先以每孔3000个人卵巢癌细胞系SKOV3接种于96孔板中，24h待细胞贴壁后，加入不同浓度活性肽(1mg/ml；0.25mg/ml；0.0625mg/ml)，并设置空白对照组。每组设置三个复孔，之后放入37℃、5％CO2浓度的恒温恒湿的细胞培养箱中培养5d，然后每孔加入20μL5mg/ml MTT继续在培养箱中培养4h。吸取培养液，加入150μL DMSO二甲基亚砜。最后在490nm波长下，在酶标仪上进行吸光度A的测定，并计算其细胞相对生存率％＝As/Ac×100。
公式中：As：活性肽样品吸光度的平均值Ac：空白对照吸光度的平均值；
活性以IC50表示，即细胞生存率达到50％时的浓度。
结果表明本发明合成的5条活性肽具有较强的抗癌活性，IC50分别为1mg/ml。
显然，本发明的上述实施例仅仅是为清楚地说明本发明所作的举例，而并非是对本发明的实施方式的限定，对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动，这里无法对所有的实施方式予以穷举，凡是属于本发明的技术方案所引伸出的显而易见的变化或变动仍处于本发明的保护范围之列。
序列表
<110> 中国科学院理化技术研究所
<120> 一种抗肿瘤活性肽及其应用
<130> JLC19I0649E
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 6
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Asp Ala Gly Pro Val Gly
1 5
<210> 2
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Glu Arg Gly Glu Glu Gly Pro Ala Gly
1 5
<210> 3
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
His Gly Asp Arg Gly Glu Leu Gly Pro Ala Gly
1 5 10
<210> 4
<211> 20
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Ala Asp Gly Asp Arg Gly Glu Ala Gly Pro Ala Gly Pro Ala Gly Pro
1 5 10 15
Ala Gly Pro Arg
20
<210> 5
<211> 21
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Gly Pro Ala Gly Pro Glu Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly
1 5 10 15
Glu Glu Gly Asp Arg
20
<210> 6
<211> 18
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
gacgccggcc ccgtgggc 18
<210> 7
<211> 27
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
gagaggggcg aggagggccc cgccggc 27
<210> 8
<211> 33
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
cacggcgaca ggggcgagct gggccccgcc ggc 33
<210> 9
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
gccgacggcg acaggggcga ggccggcccc gccggccccg ccggccccgc cggccccagg 60
<210> 10
<211> 63
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
ggccccgccg gccccgaggg ccccaggggc gacaagggcg agaccggcga ggagggcgac 60
agg 63
Claims (6)
1.一种活性肽，其特征在于，所述活性肽的氨基酸序列包括如下序列中的一种或多种：
DAGPVG；
ERGEEGPAG；
HGDRGELGPAG；
ADGDRGEAGPAGPAGPAGPR；
GPAGPEGPRGDKGETGEEGDR。
2.一种多核苷酸，其特征在于，编码权利要求1所述的任一活性肽。
3.权利要求1所述的活性肽在制备抗肿瘤药物或保健品中的应用。
4.根据权利要求3所述的应用，其特征在于，所述肿瘤为卵巢癌。
5.一种药物，其特征在于，包含权利要求1所述的活性肽。
6.一种保健品，其特征在于，包含权利要求1所述的活性肽。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910825743.5A CN110467667B (zh) | 2019-09-03 | 2019-09-03 | 一种抗肿瘤活性肽及其应用 |
| PCT/CN2019/124432 WO2021042616A1 (zh) | 2019-09-03 | 2019-12-11 | 一种抗肿瘤活性肽及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910825743.5A CN110467667B (zh) | 2019-09-03 | 2019-09-03 | 一种抗肿瘤活性肽及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110467667A true CN110467667A (zh) | 2019-11-19 |
| CN110467667B CN110467667B (zh) | 2020-11-24 |
Family
ID=68514608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910825743.5A Active CN110467667B (zh) | 2019-09-03 | 2019-09-03 | 一种抗肿瘤活性肽及其应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110467667B (zh) |
| WO (1) | WO2021042616A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021042616A1 (zh) * | 2019-09-03 | 2021-03-11 | 中国科学院理化技术研究所 | 一种抗肿瘤活性肽及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103304638A (zh) * | 2013-07-08 | 2013-09-18 | 郑州大学 | 具有抗肿瘤活性的pd-l1亲和肽及其应用 |
| CN104086627A (zh) * | 2014-05-29 | 2014-10-08 | 郑州大学 | 具有抗肿瘤活性的PD-L1 IgV亲和肽S10 |
| US20160324934A1 (en) * | 2014-01-31 | 2016-11-10 | Factor Bioscience Inc. | Methods and products for nucleic acid production and delivery |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1398324A1 (en) * | 2002-09-11 | 2004-03-17 | Fuji Photo Film B.V. | Use of recombinant gelatin-like proteins as plasma expanders and compositions suitable for plasma substitution |
| CN105586379B (zh) * | 2016-03-16 | 2019-02-15 | 中国科学院理化技术研究所 | 一种具有抑制癌细胞增殖作用的胶原蛋白活性肽的制备方法 |
| CN110028575B (zh) * | 2019-04-18 | 2022-12-30 | 成都中医药大学 | 一种小分子胶原蛋白的制备方法 |
| CN110467667B (zh) * | 2019-09-03 | 2020-11-24 | 中国科学院理化技术研究所 | 一种抗肿瘤活性肽及其应用 |
-
2019
- 2019-09-03 CN CN201910825743.5A patent/CN110467667B/zh active Active
- 2019-12-11 WO PCT/CN2019/124432 patent/WO2021042616A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103304638A (zh) * | 2013-07-08 | 2013-09-18 | 郑州大学 | 具有抗肿瘤活性的pd-l1亲和肽及其应用 |
| US20160324934A1 (en) * | 2014-01-31 | 2016-11-10 | Factor Bioscience Inc. | Methods and products for nucleic acid production and delivery |
| CN104086627A (zh) * | 2014-05-29 | 2014-10-08 | 郑州大学 | 具有抗肿瘤活性的PD-L1 IgV亲和肽S10 |
Non-Patent Citations (2)
| Title |
|---|
| U H STENMAN等: "Immunochemical demonstration of an ovarian cancer-associated urinary peptide", 《INT J CANCER》 * |
| 刘俊丽等: "胶原蛋白肽含药血清促进成骨细胞增殖和分化", 《中国骨质疏松杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021042616A1 (zh) * | 2019-09-03 | 2021-03-11 | 中国科学院理化技术研究所 | 一种抗肿瘤活性肽及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110467667B (zh) | 2020-11-24 |
| WO2021042616A1 (zh) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109400678A (zh) | 一种刺参来源的抗氧化和dpp-iv抑制活性肽 | |
| CN100587073C (zh) | 人成纤维细胞生长因子-21的重组表达 | |
| CN110627897B (zh) | 一种促进成骨细胞增殖的活性肽及其应用 | |
| CN108715600B (zh) | 一种促进肠黏膜上皮细胞增殖和迁移的寡肽及其制备方法和应用 | |
| CN103228672A (zh) | 用于从重组大肠杆菌纯化人粒细胞集落刺激因子的方法 | |
| CN101717449B (zh) | 重组TRAIL-Fc融合蛋白及其制备和应用 | |
| CN106699846B (zh) | 一种抗肥胖十一肽nalkcchscpa | |
| CN113943346B (zh) | 螺旋藻降压肽及应用 | |
| CN109251242A (zh) | 破骨细胞分化抑制用肽及其用途 | |
| CN110467667A (zh) | 一种抗肿瘤活性肽及其应用 | |
| CN109206483B (zh) | 一种贻贝来源的ace抑制及抗肿瘤活性肽 | |
| JP2001131084A (ja) | 生体コラーゲン合成促進剤 | |
| CN106749524B (zh) | 一种抗肥胖七肽npvwkrk | |
| EP0550769B1 (en) | Use of hepatocyte growth factors for the manufacture of a hemopoietic stem cell augmenting agent | |
| CN111057144B (zh) | 一种基因重组胶原寡肽mys-1及其制备方法与应用 | |
| CN108484749B (zh) | 一种重组可溶性人源骨靶向干扰素γ-1b及其制备方法 | |
| CN105237624A (zh) | 一种七肽emlqppl及其应用 | |
| CN114195857B (zh) | 一种降压肽及其制备方法和应用 | |
| CN104845949B (zh) | RGD‑重组葡激酶‑人α微球蛋白融合蛋白及其制备与应用 | |
| CN106749533B (zh) | 一种抗肥胖十七肽lnnpsvcdcdcmmkaar | |
| CN106831947A (zh) | 一种牡蛎来源的新型功能肽及其用途 | |
| CN112480210B (zh) | 一种抗凝血活性肽及其用途 | |
| CN107641154A (zh) | 一种鱿鱼生物活性肽及其制备方法 | |
| CN108101960A (zh) | 一种具有ace抑制活性和抗肿瘤的多肽分子及其制备方法 | |
| CN106868084B (zh) | 菲律宾蛤仔高活性抗肿瘤肽的制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |